You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Knowledge Management System for Multilingual Health Content

    SBC: Transcendent International, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The aim of the proposed project is to develop an advanced, web-based knowledge management system for the creation and distribution of multilingual, patient-oriented documents. The system provides a vast library of pre-translated documents and document templates for medical, educational, and administrative materials used in patient-care. System users will be abl ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

    SBC: BIOMIMETIX JV LLC            Topic: NCI

    PROJECT SUMMARY/ABSTRACT A randomized, proof-of-concept, Phase 2 clinical trial of a new class of redox-active pharmaceutical is proposed in 160 subjects undergoing primary treatment for high-grade glioma (WHO grade III and IV). Under a prior Phase II SBIR, a Phase 1 clinical trial has been completed with establishment of the recommended dose being used for this Phase 2 clinical trial. This projec ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A rationally-designed, live-attenuated RSV vaccine for the elderly

    SBC: Codagenix Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover within two weeks, but RSV is the most common cause of bronchiolitis and pneumonia in children under one year of age, and leads to hospitalization of ~177,000 adults aged 65 and older of which ~14,000 die annually. Despite many attempts, a vaccin ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Human PSMA MAb Radioimmunotherapy for Prostate Cancer

    SBC: PROGENICS PHARMACEUTICALS, INC.            Topic: N/A

    Prostate cancer is the most common cancer of men in the United States with approximately 189,000 new cases and 30,000 deaths in 2002. Recurrent disease can be controlled temporarily with androgen ablation. However, almost all prostate carcinomas eventuall

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Development of PSMA-based recombinant protein vaccines

    SBC: PROGENICS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer is the most common cancer of men in the United States with approximately 189,000 new cases and 30,000 deaths in 2002. Recurrent disease can be controlled temporarily with androgen ablation. However, alm

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  7. High-resolution Non-cryogenic Magnetoencephalography: Systems-Level Integration

    SBC: QUSPIN INC.            Topic: NIMH

    Abstract Magnetoencephalography (MEG) is an important functional neuroimaging technique that provides an excellent combination of high spatial and temporal resolution. At present, MEG scanners are handicapped by cost and complexity imposed by cryogenically cooled superconducting sensor technology. In our recently completed Phase II project, we developed new noncryogenic optical sensors that are su ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD

    SBC: OLIGOMERIX INC            Topic: R

    PROJECT SUMMARY: This R44 supplement application is focused on the development of a comprehensive publication strategy to meet the company’s long-standing goal of disseminating its findings to the scientific community. The proposed work is designed to create a long term publication plan for the company which will include the writing and publishing of (2) manuscripts during the project term. The ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. TITER ON CHIP ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION

    SBC: INDEVR, INC.            Topic: NIAID

    DESCRIPTION provided by applicant It is widely acknowledged that for split vaccines potency determination is often a rate limiting step The FDA approved andquot gold standardandquot potency assay for influenza hemagglutinin HA protein based vaccines is single radial immunodiffusion SRID SRID is a time and labor intensive assay often requiring days to complete and a minimum of hou ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government